NCT06932159View on ClinicalTrials.gov

Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 23, 2024

Primary Completion Date

March 7, 2025

Study Completion Date

April 8, 2025

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

Empagliflozin + Linagliptin film-coated tablets

1 tablet of Empagliflozin + Linagliptin 25 mg/5 mg film-coated tablets

DRUG

Glyxambi film-coated tablets

1 tablet of Glyxambi 25 mg/ 5 mg film-coated tablets

Trial Locations (1)

380 051

Veeda Clinical Research Ltd., Ahmedabad

All Listed Sponsors
lead

Humanis Saglık Anonim Sirketi

INDUSTRY

NCT06932159 - Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets | Biotech Hunter | Biotech Hunter